Veterinarians can soon prescribe a broad canine treatment that can protect against multiple parasites, including fleas, ticks, heartworms, and three different species of tapeworms.
The U.S. Food and Drug Administration (FDA) has approved Credelio Quattro, a single monthly drug reported as the broadest canine oral parasiticide. Manufactured by Elanco Animal Health Inc., the drug is the first FDA-approved parasiticide product with four active ingredients (lotilaner, moxidectin, praziquantel, and pyrantel) that can be prescribed to dogs at least eight weeks of age and as small as 3.3 lbs.
“Zoonotic disease is more common than many might think. One of our own Elanco veterinarians recently found echinococcus tapeworm lurking in her backyard,” says David Gosche, DVM, U.S. Pet Health Medical director at Elanco. “Zoonotic disease affects millions of people and animals worldwide each year. Our pets can easily serve as the ‘bridge hosts,’ bringing these parasites into our homes when they cuddle with us on couches or in our beds—making it very easy to go from ‘ick’ to ‘sick.’ That’s why we recommend year-round treatment with the broad-spectrum parasite protection in Credelio Quattro.”
Credelio Quattro comes in beef-flavored chewable tablets. It is expected to launch in the first quarter of 2025.
For more information, visit the Elanco website.